SPRY4 and prostate cancer: A recent report has shown that ETS1 knockdown in DU145 prostate cancer cells activates dual specificity phosphatase 4 (DUSP4), DUSP6, and sprouty RTK-signaling antagonist 4 (SPRY4) [58].